TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02048774

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Designation of Social Positioning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Designation of Social Positioning
Study: NCT03721549

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norwalk GI.1 Virus
Description: Norwalk virus causes viral gastroenteritis, which is also known as acute nonbacterial gastroenteritis, food poisoning, food infection, or stomach flu.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norwalk GI.1 Virus
Description: Norwalk virus causes viral gastroenteritis, which is also known as acute nonbacterial gastroenteritis, food poisoning, food infection, or stomach flu.
Study: NCT04461145

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: command
Description: The participant was asked to walk along the walkway while backward counting numbers with increment of seven starting from a randomly given number.
Study: NCT00820313

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dr. Dean Ornish Program for Reversing Heart Disease
Description: Exercise: At least 3 hours of aerobic exercise per week, 30 minutes per session. Additionally, patients are asked to perform a minimum of 2 strength training sessions per week.~Stress Management: Integrates stretching, relaxation, breathing techniques, meditation and guided imagery. Patients are asked to practice these techniques at least 1 hour per day.~Diet: Approximately 10% daily calories from fat, 15% protein and 75% complex carbohydrates (low-fat, whole foods, primarily plant-based).~Group Support: Weekly group support sessions provide social support to help patients adhere to and sustain the lifestyle-change program.
Study: NCT02576093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% WOL071-007
Description: Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% WOL071-007
Description: Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0% WOL071-007
Description: Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of WOL071-007
Description: Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
Study: NCT01960192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD-MTX-Ara-C regimen
Description: high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FVD regimen
Description: FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
Study: NCT04225806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BlueLeaf® Endovenous Valve Formation System (BlueLeaf System)
Description: The BlueLeaf System is a single-use, disposable device designed to modify the vein wall to form one or more functional autogenous valves to improve the hemodynamics of the deep venous system treated.
Study: NCT03856749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote wheelchair skills training
Description: Prior to the first training session, the trainer will be provided with the results from the assessment immediately preceding training to provide him/her time to individualize the training session. Trainer will provide self-study materials (the Caregiver Handbook and caregiver-training video-recording) and an explanation on how these materials should be used.~The wheelchair user and caregiver will be trained together on wheelchair skills, using the principles of the Wheelchair Skills Training Program, as outlined in the Wheelchair Skills Program Manual using remote technology. Each training session will be with a trainer-to-dyad ratio of 1:1 1 dyad = 1 manual wheelchair user + his/her caregiver. Training will continue until the goals have been met and retained (for at least one subsequent session), using up to 4 training sessions that will each last up to 60 minutes at intervals a minimum of 3 days.
Study: NCT03563586

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bowel Preparation plus antibiotics
Description: Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)

Intervention type: OTHER
Group type: OTHER
Intervention: Bowel Preparation
Description: Mechanical Bowel Preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm) alone Both groups will receive iv antibiotics (cefoxitin 2 gr plus metronidazole 500gr) perioperatively and discontinuation within 24 hours
Study: NCT01079208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test starter infant formula
Description: infants are fed for 6 months with this starter formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test starter infant formula with synbiotics
Description: infant are fed for 6 months with this formula

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control standard formula
Description: infant are fed 6 months with this formula
Study: NCT00811395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration
Study: NCT02635139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dinner skipping
Description: 18h fasting period in the evening
Study: NCT03739489

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation was a technique able to modulate the brain circuit restoring the function.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation was a technique able to modulate the brain circuit restoring the function.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation was a technique able to modulate the brain circuit restoring the function.
Study: NCT01665079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol was administered by plasma TCI and a bolus dose was given by setting the initial plasma target between 12-16 μg/ml according to the anesthesiologist criteria. The protocol target range was selected based on previous experience using this model in the obese. After the patients reached this target, propofol infusion was stopped until the patients woke up (BIS\>75). No other drugs were given during this period. Facemask ventilation was assisted only if necessary to maintain SpO2 \> 90%. BIS data and propofol infusion data were automatically recorded every five seconds using the AnestFusor© program. Arterial blood samples of 4 ml for propofol assays were collected at 1, 2, 3, 5, 7 and 10 minutes after the initial bolus dose or until BIS \> 75. After the patient woke up the study was considered finished and propofol infusion was restarted according to the anesthesiologist plan.
Study: NCT01690559

Intervention type: DRUG
Intervention: Cipro (Ciprofloxacin, BAYQ3939)
Description: Patient treated with Ciproxan without dilution treatment in daily clinical practice
Study: NCT02840643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bimanual hand therapy
Description: Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive bimanual hand therapy, which involves actively using both hands in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bimanual hand therapy
Description: Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive bimanual hand therapy, which involves actively using both hands in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint therapy
Description: Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive constraint therapy, which involves actively using the impaired hand in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint therapy
Description: Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive constraint therapy, which involves actively using the impaired hand in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
Study: NCT03414255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Micronized DHACM
Description: 1 mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: Injection of 1mL 0.9% Sodium Chloride Injection, USP
Study: NCT03252249

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 months dual anti-platelet therapy
Description: Patients with acute coronary syndrome will be randomised to 3 months dual anti-platelet therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12 months dual anti-platelet therapy
Description: Patients with acute coronary syndrome will be randomised to 12 months dual anti-platelet therapy.
Study: NCT02854488

Intervention type: DRUG
Intervention: Yervoy
Study: NCT00888329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: 40 mg administered orally with a sip of water prior to anesthesia induction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02051153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil (2-\[(Diphenylmethyl) sulfinyl\]acetamide (Provigil, 1997)) is a novel drug which has a demonstrable efficacy in the treatment of daytime sleepiness associated with narcolepsy (Benerjee et al., 2004). Studies on healthy volunteers show that modafinil improves neuropsychological task performance in some healthy individuals (Turner et al., 2004; Baranski et al., 2004; MÜller et al., 2004; Randall et al., 2005) and in patients with neuropsychiatric disorders (Minzenberg \& Carter, 2008).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00811395

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for teriflunomide)
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for teriflunomide)
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interferon-β [IFN-β]
Description: Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-β [IFN-β]
Description: Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-β [IFN-β]
Description: Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glatiramer Acetate [GA]
Description: Solution in prefilled syringe for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate [GA]
Description: Solution in prefilled syringe for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate [GA]
Description: Solution in prefilled syringe for subcutaneous injection
Study: NCT04170855

Intervention type: DRUG
Group type: OTHER
Intervention: Furosemide Injection
Description: We will measure kidney sodium content in patient with cardiorenal syndrome. we will inject within the week of this first measurement furosemide only in patient who will be resistant to diuretics (Based on these parameters, diuretic response will be defined as:~* A reduction in fractional spot urinary sodium~* An increase in urinary volume~* A \>1 kg reduction in body weight within 24 hours from diuretic administration (extrapolation of guidance on management of acute HF) and we will do another measurement of kidney sodium content after furosemide injection.
Study: NCT04095962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The MT program will be conducted for 6 months, twice a week in 60 minutes sessions. Sessions will be divided in warm-up (10 minutes, including slow walk, postural and mobility exercises for general activation, and stretching exercises), specific training (35-45 minutes, including balance/coordination training, strength and aerobic exercises) and cool down (5 minutes with breathing and stretching exercises for the main worked joints and muscles) following the main guidelines recommended by the American College of Sports Medicine \[18\] and the WHO \[19\].
Study: NCT01855139

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 15 mg OD or 20 mg OD
Study: NCT02092506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 day triple therapy
Description: 10 day triple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 day sequential therapy
Description: 10 day sequential therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 day concomitant therapy
Description: 10 day concomitant therapy
Study: NCT01962909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTP-01
Description: Dose level 1 is 10mCi (50ug of peptide)
Study: NCT00779116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyrtec® (cetirizine)
Description: Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyrtec® (cetirizine)
Description: Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day
Study: NCT02203916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azilsartan medoxomil placebo
Description: Azilsartan medoxomil placebo-matching tablets
Study: NCT02729870

Intervention type: DRUG
Intervention: Oral Glucose Gel
Description: This group will receive the following: are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.

Intervention type: OTHER
Intervention: Placebo
Description: This group will receive carboxymethylcellulose (2%) oral gel. The subjects who are less than than 3 years of age will receive carboxymethylcellulose (2%) oral gel, 20ml which will be a one time dose and the subjects ages 3-7 will receive carboxymethylcellulose (2%) oral gel, 40ml which will be a one time dose.
Study: NCT03094481

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCPB
Description: Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Superficial Cervical Plexus Block at C4 or C5.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCPB
Description: Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Superficial Cervical Plexus Block at C4 or C5.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISB
Description: Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Interscalene Brachial Plexus Block at C5 or C6.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISB
Description: Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Interscalene Brachial Plexus Block at C5 or C6.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCPB + ISB
Description: Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided SCPB at C4 or C5 + 10ml injected for ISB at C5 or C6.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCPB + ISB
Description: Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided SCPB at C4 or C5 + 10ml injected for ISB at C5 or C6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrogen chloride , epinephrine
Description: Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrogen chloride , epinephrine
Description: Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrogen chloride , epinephrine
Description: Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrogen chloride , epinephrine
Description: Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrogen chloride , epinephrine
Description: Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrogen chloride , epinephrine
Description: Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine
Study: NCT02295254

Intervention type: OTHER
Intervention: feces sample
Description: The travelers will give feces sample before and after the travel. The sample microorganisms will be analyzed.
Study: NCT01832051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-trastuzumab injection
Study: NCT02428387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Tools 4 Care
Description: On-line self-administered (My Tools 4 Care) transition toolkit includes interactive activities and resources to help caregivers deal with their transitions
Study: NCT02177604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wingate HIT
Description: 3 sessions of Wingate based High-Intensity Interval Training (6-8 x 15 second all out sprints on a cycle ergometer interspersed by 2 minutes recovery)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified HIT
Description: 3 sessions of Modified High-Intensity Interval Training (8 x 60 second sprints at approximately 90-95% VO2 peak on a cycle ergometer interspersed by 60 seconds recovery)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat overfeeding
Description: 7 days of high-fat overfeeding (50% excess calories)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-fat overfeeding
Description: 7 days of high-fat overfeeding (50% excess calories)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat overfeeding
Description: 7 days of high-fat overfeeding (50% excess calories)
Study: NCT03483012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a protein that affects your immune system by blocking the PD-L1 pathway

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Description: Stereotactic radiosurgery (SRS) is a standard procedure used to treat patients with cancer in the brain. SRS uses many precisely focused radiation beams to treat tumors
Study: NCT04207944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulindac 400 MG
Description: Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
Study: NCT01375699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: As prescribed by treating provider.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Given PO, by mouth
Study: NCT04275583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3602
Description: This is a kind of proteasome inhibitor.